News & Updates

Treatment with nonvitamin K antagonist oral anticoagulants (NOACs) results in lower risks of diabetes complications and mortality compared with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus (DM), suggest a study.

In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).

The early addition of ivermectin to standard of care (SoC)* in high-risk patients with mild-to-moderate COVID-19 did not prevent progression to severe disease compared with SoC alone, according to results of the I-TECH** trial conducted in Malaysia.

The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.

In the phase II/III RELATIVITY-047 trial evaluating dual checkpoint inhibition for advanced melanoma, a new fixed-dose combination comprising the LAG-3 inhibitor relatlimab and the PD-1 inhibitor nivolumab fared better than nivolumab monotherapy.